In a briefing document for an advisory committee meeting this week, the FDA signaled support for Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo (RSVpreF), which has shown to reduce risk of severe infection by 81 percent in infants whose mothers received it while pregnant.
Source: Drug Industry Daily